Ava names Dr. Maja Rudinac new Chief Technology Officer

ZURICH and SAN FRANCISCO, Nov 8, 2021 / — Ava, a medical technology company focused on innovations in women's reproductive health, has named Dr. Maja Rudinac to the position of Chief Technology Officer.  

An entrepreneur and AI inventor who previously served as a CEO and CTO of multiple startups in robotics and healthcare AI, Rudinac will lead technology development at Ava. Reporting directly to Ava CEO Lea von Bidder, Rudinac will enhance the integration with B2B partners through new product and feature development. Ava is aggressively expanding its technology offerings for payers and providers.  

“Maja’s addition to the executive team strengthens Ava's unique position as the most data driven and technologically advanced company in the fertility benefits space,” said von Bidder. "Her focus on the data and technology needs of women, employers, benefits providers, and OB/GYNs will enable us to accelerate our innovative offerings for these partners.” 

Ava's AI-driven fertility platform includes the Ava bracelet, which is worn only at night. It saw incredible consumer success before being adopted by fertility benefit providers as a cost-saving alternative to traditional treatments. The company will soon add contraception to its platform. 

Rudinac brings to Ava more than 15 years’ experience in designing and bringing to market AI and robotics-driven healthcare applications, including AI-enabled homes for safe senior living and autonomous healthcare systems for people with motion and cognitive restrictions. Prior to her role as VP of BD at Caspar.AI, she was co-founder and CEO of Robot Care Systems. The company received the prestigious Red Dot design award, Shell and Accenture Innovation awards, as well as the Herman Wijffels Innovation Award for the best healthcare invention. In 2019, Rudinac received the Royal Prince Friso Engineering Award. 

"Joining the team gives me an incredible opportunity to build on Ava's unique strengths in the benefits space,” said Rudinac. “We already have a large consumer user base, clinical and regulatory validation—now we are deeply investing in product development to meet the needs of payers and providers.” 

About Ava  

Ava is a digital health company with offices in Zurich, San Francisco, Belgrade, and Makati that advances women’s reproductive health by bringing together artificial intelligence and clinical research. It has an FDA cleared fertility platform.  

Its fertility tracking sensor bracelet detects the five most fertile days of a woman’s cycle in real-time with 90% accuracy, while also delivering personalized insight about reproductive health and pregnancy. Launched in 2016, Ava Fertility has a large, happy user base, clinical validation in multiple clinical trials, and regulatory validation through its FDA and European clearances. 

Studies for the clinical use of Ava have been conducted in collaboration with academic partners around the world, including at the University Hospital of Zurich, Switzerland, Columbia University, and Northwestern University’s Feinberg School of Medicine. Ava was voted Best of Baby Tech at CES, named a Women’s Health “Editors’ Choice” product and has been honored as a CB Insights Digital Health 150 company. For more information on Ava, visit www.avawomen.com. 

Ava is FDA cleared, and CE-marked according to MDR 2017/745 for the purpose of measuring and displaying physiological parameters to facilitate conception and to provide general information on health and wellness to users.